The information contained in this section of Pharma Equity Group A/S’ (the “Company”) web page that you are attempting to access is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, together, the “United States”), Canada, Australia and Japan, or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction, and does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any shares or other securities of the Company in the United States, Canada, Australia, Japan or any jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

The shares of the Company with respect to (i) new shares to the shareholders of Reponex Pharmaceuticals A/S as payment for their shares in Reponex Pharmaceuticals A/S in connection with the Company’s conditional takeover offer of the total issued and outstanding share capital of Reponex Pharmaceuticals A/S (the “Transaction”), (ii) new rights issue shares issued with pre-emptive rights to the existing shareholders of the Company prior to completion of the Transaction in a rights issue and (iii) the admission to trading and official listing of previously unlisted class b-shares in connection with the merger of the Company’s previously issued share classes referred to herein and on the following web page (the “Shares”) have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority under any applicable securities laws of any state, province, territory, county or jurisdiction of the United States or any other restricted jurisdiction. The Shares may not be offered, sold, resold, pledged, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States absent registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state and other securities laws of the United States, or any other restricted jurisdiction. No public offering of the Shares is being, has been or will be made in the United States. Any Shares sold in the United States will be sold only to persons reasonably believed to be qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A under the Securities Act. The information contained herein and on the following web page does not constitute, and should not be construed as, an offer to sell or solicitation of an offer to buy any of the Shares in the United States, “general solicitation or general advertising” under Rule 502(c) of Regulation D under the Securities Act or “directed selling efforts” under Regulation S of the Securities Act.